FATE
Fate Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.48
+2.48%Margins
Gross margin
-343.0%
EBITDA margin
-1805.3%
EBIT margin
-2058.1%
Net margin
-1941.1%
FCF margin
-1627.8%
-82.1%
Return on equity
-48.4%
Return on assets
-58.3%
Return on invested capital
0.02x
Asset turnover
-$101.9M
Cash from operations
$1.28
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026